Topical Minoxidil Fortified with Finasteride: Maintenance of Hair Density After Replacing Oral Finasteride

In this triple-blind randomized clinical trial, researchers found that oral minoxidil 0.25 mg tablets were as effective as 2% topical minoxidil for increasing hair diameter and density in women with female pattern hair loss, with similarly minor side effects.

This study found that treating male pattern androgenetic alopecia with a combination of topical minoxidil and finasteride resulted in better outcomes for hair growth and density compared to using minoxidil alone.

This study reported that among postmenopausal women with female pattern hair loss, treatment with topical finasteride 0.5% and minoxidil 2% was more effective at improving hair condition than treatment with topical 17α-estradiol 0.05% and minoxidil 2%, particularly notable at 12-18 months of follow-up.

This study reported that combined oral finasteride and topical 5% minoxidil treatment in men with male-pattern hair loss improved hair growth by initiating anagen in pre-existing but deficient follicles, yet the growth rates remained unchanged and did not normalize hair productivity.

Oral minoxidil helps female hair loss, topical finasteride treats AGA, and sulfotransferase activity predicts minoxidil effectiveness.

This study found that among patients with stage III and IV androgenic alopecia, 83% of those using topical 5% minoxidil with topical 0.1% finasteride showed improved hair density, suggesting it may reduce the need for long-term oral finasteride.

In this study, the therapeutic response of topical minoxidil solution was not significantly enhanced by adding topical finasteride, questioning its additional value in treating male pattern androgenetic alopecia.

This study found that JetPeel-assisted topical minoxidil significantly improved hair growth in patients with androgenetic alopecia compared to topical minoxidil alone or no treatment.

In this study, finasteride was found to be more effective than 5% minoxidil for treating male androgenetic alopecia in Chinese patients, with combination therapy showing the greatest improvement.

This study found that a combination of topical minoxidil and finasteride helped maintain hair density in patients with androgenetic alopecia after initial oral finasteride treatment.

This study found that a topical solution of caffeine and minoxidil 2.5% was more effective in treating androgenetic alopecia than minoxidil 2.5% alone.

This study found that while the combination therapy of 3% minoxidil and 0.1% finasteride lotion showed greater improvement in global photographic assessments for androgenetic alopecia, hair counts did not differ significantly from minoxidil alone.

This study suggests that 5 mg/day oral finasteride may increase hair density and thickness in normoandrogenic Asian women with female pattern hair loss over 12 months.

This study found that topical 5% minoxidil solution is effective and well tolerated for promoting hair growth in Korean men with androgenetic alopecia over 24 weeks.

In this 48-week trial, 5% topical minoxidil was more effective than both 2% minoxidil and placebo in promoting hair growth in women with female pattern hair loss, with notable improvements in nonvellus hair count and hair growth assessments.

This study found that oral finasteride was more effective than 5% topical minoxidil in treating mild to severe androgenetic alopecia in males, with both treatments deemed effective and safe over 12 months.

This study found that 5% topical minoxidil significantly increased hair regrowth and improved psychosocial perceptions of hair loss in men with androgenetic alopecia compared to 2% topical minoxidil and placebo over 48 weeks.

This study found that combining oral finasteride with topical minoxidil resulted in the greatest improvement in hair growth for male patients with androgenetic alopecia, compared to using any single treatment.

This case report discusses a 32-year-old man's treatment for advanced androgenetic alopecia using a combination of topical minoxidil and oral finasteride, but no clinical outcomes are detailed.